Arun Danewa: Saving a Bone Marrow Patient from Hidden Enemy – TA-TMA
Arun Danewa, Senior Consultant at Artemis Hospitals, shared a post on LinkedIn:
“The Blood Vessel Mystery: Saving a Bone Marrow Patient
Think of a Bone Marrow Transplant (BMT) as a total system restart. It’s a lifesaving process, but sometimes the ‘new system’ hits a dangerous glitch.
In this case, a patient recovering from severe aplastic anemia survived a massive infection (MDR Sepsis) only to face a new, hidden enemy:
Transplant Associated Thrombotic microangiopathy (TA-TMA).
The Red Flags
How do you know when something is wrong?
The body starts sending ‘SOS’ signals.
For our patient, those signals were:
- High Blood Pressure: The heart was working too hard.
- Protein in Urine: A sign the kidneys were struggling.
- Crushed Red Cells: Under the microscope, we saw Schistocytes—red blood cells that looked like they’d been shattered.
These ‘alarm bells’ pointed to TA-TMA, a condition where tiny blood clots start forming in the small vessels, damaging organs.
The Rescue Plan
To fix this, we had to act like detectives and change our strategy fast:
- Stop the ‘Trigger’: We realized a specific medicine the patient was taking to prevent transplant rejection (Cyclosporine) was actually causing the damage. We stopped it immediately.
- Switch the Shield: To keep the patient safe from rejection, we switched them to Steroids instead.
- Double-Check the Enemy: We ran a special test (ADAMTS13) to make sure this wasn’t a different, rarer blood disorder. The test confirmed we were on the right track.
The Result: A Huge Comeback
In just 11 days, the patient’s body began to heal. The ‘stress’ markers in their blood dropped, and their healthy cell counts climbed back up.
The Lesson
In transplant medicine, watching closely saves lives. By catching high blood pressure and kidney changes early, we can stop a major complication before it does permanent damage. It’s all about knowing when to change the plan to fit the patient’s needs.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines
-
Nov 15, 2026, 20:50Asmaa Beltagy: Efficacy and Safety of Eltrombopag in SLE-Associated Immune Thrombocytopenia
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP